Literature DB >> 25447915

A methods review on use of nonsense suppression to study 3' end formation and other aspects of tRNA biogenesis.

Keshab Rijal1, Richard J Maraia2, Aneeshkumar G Arimbasseri3.   

Abstract

Suppressor tRNAs bear anticodon mutations that allow them to decode premature stop codons in metabolic marker gene mRNAs, that can be used as in vivo reporters of functional tRNA biogenesis. Here, we review key components of a suppressor tRNA system specific to Schizosaccharomyces pombe and its adaptations for use to study specific steps in tRNA biogenesis. Eukaryotic tRNA biogenesis begins with transcription initiation by RNA polymerase (pol) III. The nascent pre-tRNAs must undergo folding, 5' and 3' processing to remove the leader and trailer, nuclear export, and splicing if applicable, while multiple complex chemical modifications occur throughout the process. We review evidence that precursor-tRNA processing begins with transcription termination at the oligo(T) terminator element, which forms a 3' oligo(U) tract on the nascent RNA, a sequence-specific binding site for the RNA chaperone, La protein. The processing pathway bifurcates depending on a poorly understood property of pol III termination that determines the 3' oligo(U) length and therefore the affinity for La. We thus review the pol III termination process and the factors involved including advances using gene-specific random mutagenesis by dNTP analogs that identify key residues important for transcription termination in certain pol III subunits. The review ends with a 'technical approaches' section that includes a parts lists of suppressor-tRNA alleles, strains and plasmids, and graphic examples of its diverse uses. Published by Elsevier B.V.

Entities:  

Keywords:  RNA polymerase III; RPC11; RPC2; RPC37; RPC53; Transcription termination

Mesh:

Substances:

Year:  2014        PMID: 25447915      PMCID: PMC4272643          DOI: 10.1016/j.gene.2014.11.034

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  171 in total

1.  Structural basis of transcription: alpha-amanitin-RNA polymerase II cocrystal at 2.8 A resolution.

Authors:  David A Bushnell; Patrick Cramer; Roger D Kornberg
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

Review 2.  La protein and its associated small nuclear and nucleolar precursor RNAs.

Authors:  Richard J Maraia; Robert V Intine
Journal:  Gene Expr       Date:  2002

Review 3.  Eukaryotic ribonuclease P: a plurality of ribonucleoprotein enzymes.

Authors:  Shaohua Xiao; Felicia Scott; Carol A Fierke; David R Engelke
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

4.  Aberrant nuclear trafficking of La protein leads to disordered processing of associated precursor tRNAs.

Authors:  Robert V Intine; Miroslav Dundr; Tom Misteli; Richard J Maraia
Journal:  Mol Cell       Date:  2002-05       Impact factor: 17.970

Review 5.  The La protein.

Authors:  Sandra L Wolin; Tommy Cedervall
Journal:  Annu Rev Biochem       Date:  2001-11-09       Impact factor: 23.643

6.  Maf1 is an essential mediator of diverse signals that repress RNA polymerase III transcription.

Authors:  Rajendra Upadhya; JaeHoon Lee; Ian M Willis
Journal:  Mol Cell       Date:  2002-12       Impact factor: 17.970

7.  Isolation and cloning of four subunits of a fission yeast TFIIIC complex that includes an ortholog of the human regulatory protein TFIIICbeta.

Authors:  Y Huang; M Hamada; R J Maraia
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

8.  Widespread use of TATA elements in the core promoters for RNA polymerases III, II, and I in fission yeast.

Authors:  M Hamada; Y Huang; T M Lowe; R J Maraia
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

9.  Essential roles of Bdp1, a subunit of RNA polymerase III initiation factor TFIIIB, in transcription and tRNA processing.

Authors:  Akira Ishiguro; George A Kassavetis; E Peter Geiduschek
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

Review 10.  Transcription termination by the eukaryotic RNA polymerase III.

Authors:  Aneeshkumar G Arimbasseri; Keshab Rijal; Richard J Maraia
Journal:  Biochim Biophys Acta       Date:  2012-10-23
View more
  7 in total

Review 1.  Nonsense suppression therapies in human genetic diseases.

Authors:  Patrícia Martins-Dias; Luísa Romão
Journal:  Cell Mol Life Sci       Date:  2021-03-22       Impact factor: 9.261

Review 2.  RNA Polymerase III Advances: Structural and tRNA Functional Views.

Authors:  Aneeshkumar G Arimbasseri; Richard J Maraia
Journal:  Trends Biochem Sci       Date:  2016-04-08       Impact factor: 13.807

3.  RNA Polymerase III Output Is Functionally Linked to tRNA Dimethyl-G26 Modification.

Authors:  Aneeshkumar G Arimbasseri; Nathan H Blewett; James R Iben; Tek N Lamichhane; Vera Cherkasova; Markus Hafner; Richard J Maraia
Journal:  PLoS Genet       Date:  2015-12-31       Impact factor: 5.917

4.  Lack of tRNA-i6A modification causes mitochondrial-like metabolic deficiency in S. pombe by limiting activity of cytosolic tRNATyr, not mito-tRNA.

Authors:  Tek N Lamichhane; Aneeshkumar G Arimbasseri; Keshab Rijal; James R Iben; Fan Yan Wei; Kazuhito Tomizawa; Richard J Maraia
Journal:  RNA       Date:  2016-02-08       Impact factor: 4.942

Review 5.  Factors That Shape Eukaryotic tRNAomes:  Processing, Modification and Anticodon-Codon Use.

Authors:  Richard J Maraia; Aneeshkumar G Arimbasseri
Journal:  Biomolecules       Date:  2017-03-08

6.  Targeting mitochondrial and cytosolic substrates of TRIT1 isopentenyltransferase: Specificity determinants and tRNA-i6A37 profiles.

Authors:  Abdul Khalique; Sandy Mattijssen; Alexander F Haddad; Shereen Chaudhry; Richard J Maraia
Journal:  PLoS Genet       Date:  2020-04-23       Impact factor: 5.917

7.  Active Center Control of Termination by RNA Polymerase III and tRNA Gene Transcription Levels In Vivo.

Authors:  Keshab Rijal; Richard J Maraia
Journal:  PLoS Genet       Date:  2016-08-12       Impact factor: 5.917

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.